Isentress Re-examination Study (MK-0518-115)
NCT01042808 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 996
Last updated 2015-07-21
Summary
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Isentress through collecting the safety and efficacy information in usual practice according to the Re-examination Regulation for New Drugs.
Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Conditions
- HIV Infection
- HIV Infections
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Monitor · Merck Sharp & Dohme LLC
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2014-05-31
- Completion
- 2014-05-31
More Related Trials
-
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
NCT03188523 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
NCT04003103 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)
NCT02217904 ·Status: COMPLETED ·Phase: PHASE1
-
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
NCT05630755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
NCT04233879 ·Status: COMPLETED ·Phase: PHASE3
-
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
NCT05494736 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
NCT00158821 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)
NCT02174159 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
NCT00823966 ·Status: COMPLETED
-
Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)
NCT04223778 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
NCT00100048 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination of Efavirenz and Truvada - COMET Study
NCT00224458 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of an Investigational Drug in Human Immunodeficiency Virus (HIV)-Infected Patients Failing Current Antiretroviral Therapies (0518-005)(COMPLETED)
NCT00105157 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)
NCT03615183 ·Status: COMPLETED ·Phase: PHASE1
-
Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
NCT04515641 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)
NCT02397096 ·Status: COMPLETED ·Phase: PHASE3
-
Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)
NCT04223791 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants
NCT01656018 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
NCT00293267 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
NCT06630299 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
NCT06630286 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
NCT00002453 ·Status: COMPLETED ·Phase: NA
-
Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz
NCT01160120 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV
NCT05052996 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2